drugset / Trial / NCT01732107
Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression
Phase 2
Terminated
13 enrolled
Noah Hahn, M.D.
Hoosier Cancer Research Network · collabNovartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial will assess the 6-month complete response rate and toxicity profile of oral dovitinib therapy in BCG-refractory urothelial carcinoma patients with tumors with FGFR3 mutations or over-expression who are ineligible for or refusing cystectomy.
Timeline
- Start
- 2013-03
- Primary completion
- 2017-03-06
- Completion
- 2017-03-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dovitinib | Small molecule | 500 mg | Oral |